How Nemifitide diTFA can Save You Time, Stress, and Money.
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key trial goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis p